Provision of information to the health technology developer on engagement in joint scientific consultations
Article 4
1. With regard to joint scientific consultations on medicinal products, the information referred to in Article 17(4) of Regulation (EU) 2021/2282 shall be provided by the JSC Subgroup via the HTA secretariat and shall, where applicable, include a timetable for the joint scientific consultation. 2. Within 15 working days after the end of each request period, the HTA secretariat shall notify the European Medicines Agency of the list of the granted requests for joint scientific consultation on medicinal products to be carried out in parallel with the scientific advice. 3. Where the health technology developer requests the joint scientific consultation to be carried out in parallel with the scientific advice, the timetable referred to in paragraph 1 shall be agreed between the HTA secretariat, in consultation with the JSC Subgroup, and the European Medicines Agency and shall be synchronised with the timing of the process for scientific advice as specified in Article 7(5), points (a) and (c), Article 9(2), point (a), Article 12(2) and Article 13(2), point (b).